An interventional study of Caffeine and Placebo in Hypertension and Healthy, sponsored by Florida State University. Completed. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-29.
Sponsored by Florida State University · Not applicable, Interventional, and Other
Caffeine is an exceedingly popular and consumed pharmacological agent. Although caffeine is primarily consumed from coffee and tea beverages, it is also available in other forms such as sodas, energy drinks, tablets and capsules. Nevertheless, caffeine acutely increases brachial and aortic systolic blood pressure (BP) and arterial stiffness. Arterial stiffness is an independent predictor of cardiovascular disease (CVD) and assessed through pulse wave velocity (PWV). Interestingly, previous studies have proposed that caffeine may increase aortic BP through increases in aortic PWV and augmentation index (AIx), a measurement of wave reflection. Yet, these effects were seen in middle-aged adults with treated hypertension and a wide age range. Therefore, it is imperative to consider that caffeine may cause different effects in young normotensive individuals than in older adults independently of BP levels. Importantly, oral supplementation of the amino-acid, L-citrulline has been shown to enhance the bioavailability of L-arginine levels and nitric oxide (NO) production and, therefore, improve arterial function. L-citrulline supplementation for 7 days given at 6 g/day has shown to increase NO levels while improving PWV. Previous studies by our group also demonstrated that L-citrulline supplementation reduces the BP response to cold exposure; a condition with an increased vasoconstriction. Therefore, the acute effects of caffeine on central and peripheral PWV and BP in healthy young men are yet to be fully evaluated. We hypothesized that acute caffeine intake would increase peripheral and aortic BP and PWV and that L-citrulline supplementation would attenuate the effects induced by acute caffeine ingestion.
The specific aims of this study are:
AIM 1: To examine the effects of the acute ingestion of 200mg caffeine (tablets) on arterial function in young adults. The working hypothesis is that acute caffeine intake would increase brachial, ankle and aortic BP, PWV (aortic and leg), and wave reflection. In order to test this hypothesis, the investigators will perform non-invasive measurements of arterial stiffness (aortic and leg PWV) and pulse wave analysis (aortic BP and AIx) using applanation tonometry of the radial artery 30, 45, and 60 minutes following caffeine ingestion.
AIM 2: To determine the effectiveness of L-citrulline supplementation to attenuate the acute cardiovascular effects of caffeine ingestion. The working hypothesis is that 7 days of L-citrulline supplementation will attenuate the unfavorable arterial responses (increases in BP, PWV, and wave reflection) to acute caffeine ingestion. In order to test this hypothesis, the investigators will perform the same procedures previously specified in AIM 1.
Description of the study:
Sixteen healthy young men 18-40 years of age will be enrolled in this study. Participants with CVD history, resting BP (> 160/100 mmHg), recent history of smoking, or considered competitive athlete will be excluded from the study. All subjects will refrain from food and caffeine for > 8 hours and from exercise for > 24 hours before testing.
Study design:
Following an initial screening, arterial function measurements will be collected. Measurements will be assessed at baseline following 10 minutes of rest in the supine position and then again at 30, 45, and 60 minutes after 200 mg caffeine or placebo ingestion. Participants will receive caffeine or placebo supplementation on two separate visits with a minimum of 48 hours in between sessions. Following the acute phase of the study, subjects will be randomized to consume L-citrulline or placebo for 7 days given at 6 grams/day. Following the same protocol as the acute phase with 200 mg caffeine, measurements will be collected before and after the 7 day supplementation period.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 16 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Florida State University is the lead sponsor of 241 studies on the registry; 46 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 9 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
200 mg caffeine tablet produced by CVS Pharmacy, USA
Drug: Caffeine
Placebo pill produced by NOW FOODS, USA
Drug: Placebo
L-citrulline capsule (750 mg) provided by NOW FOODS
Dietary Supplement: L-citrulline
A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
Also known as: Caffeine tablet (CVS Pharmacy)
A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
Also known as: Placebo from NOW FOODS, USA
L-citrulline was used to examine the effect of the supplement on arterial function.
Also known as: L-citrulline (750 mg/capsule)
Aortic Blood Pressure
Aortic blood pressure at rest and 30 minutes after acute ingestion of 200 mg of caffeine before and after 7 days of either 6g/day of Citrulline or 6 g/day of Placebo.
Time frame: Baseline and Day 7 (Calculated change between rest and 30 minutes post-caffeine ingestion at these time points)
Changes in Reflected Wave Pressure (P2)
Reflected wave pressure at rest and 30 minutes after ingestion of 200mg of caffeine after 7 days supplementation of 6g/day of either L-Citrulline or Placebo.
Time frame: Baseline and Day 7 (Calculated change between rest and 30 minutes post-caffeine ingestion at these time points)
Changes in Femoral-ankle Pulse Wave Velocity After 7 Days of Either L-Citrulline or Placebo (6g/Day)
Femoral-ankle pulse wave velocity at rest and 30 minutes after ingestion of 200mg of caffeine after 7 days supplementation of 6g/day of either L-Citrulline or Placebo.
Time frame: Baseline and Day 7 (Calculated change between rest and 30 minutes post-caffeine ingestion at these time points)
Sixteen young healthy men participated in this study. All subjects were non-smokers, recreationally active, and free of apparent cardiovascular-metabolic diseases based on medical history.
| Milestone | Citrulline First, Then Placebo | Placebo First, Then L-Citrulline |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
| Milestone | Citrulline First, Then Placebo | Placebo First, Then L-Citrulline |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
| Milestone | Citrulline First, Then Placebo | Placebo First, Then L-Citrulline |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Aortic blood pressure at rest and 30 minutes after acute ingestion of 200 mg of caffeine before and after 7 days of either 6g/day of Citrulline or 6 g/day of Placebo.
| mmHg | Citrulline | Placebo |
|---|---|---|
| Baseline | 5 ± 1 | 6 ± 1 |
| 7 Days | 4 ± 1 | 4 ± 1 |
Reflected wave pressure at rest and 30 minutes after ingestion of 200mg of caffeine after 7 days supplementation of 6g/day of either L-Citrulline or Placebo.
| mmHg | Citrulline | Placebo |
|---|---|---|
| Baseline | 5 ± 1 | 5 ± 1 |
| 7 Days | 4 ± 1 | 5 ± 1 |
Femoral-ankle pulse wave velocity at rest and 30 minutes after ingestion of 200mg of caffeine after 7 days supplementation of 6g/day of either L-Citrulline or Placebo.
| m/s | Citrulline | Placebo |
|---|---|---|
| Baseline | 0.6 ± 0.4 | 0.7 ± 0.5 |
| 7 Days | 0.4 ± 0.4 | 0.6 ± 0.4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Citrulline | — | — | — |
| Placebo | — | — | — |
| Age, Categorical(Participants) | L-Citrulline or Placebo |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 16 |
| >=65 years | 0 |
| Age, Continuous(years) | L-Citrulline or Placebo |
|---|---|
| Mean | 23 ± 3 |
| Sex: Female, Male(Participants) | L-Citrulline or Placebo |
|---|---|
| Female | 0 |
| Male | 16 |
| Sex: Female, Male(Participants) | L-Citrulline or Placebo |
|---|---|
| Female | 0 |
| Male | 16 |
| Race and Ethnicity Not Collected(Participants) | L-Citrulline or Placebo |
|---|
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Florida State University